What Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Sell
46
KOD Quote, Financials, Valuation and Earnings
Last price:
$4.07
Seasonality move
:
5.71%
Day range:
$3.90 - $4.19
52-week range:
$1.92 - $11.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.41x
Volume:
317.7K
Avg. volume:
459.1K
1-year change:
5.22%
Market cap:
$212.6M
Revenue:
--
EPS (TTM):
-$3.65
Analysts' Opinion
-
Consensus RatingKodiak Sciences has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.80, Kodiak Sciences has an estimated upside of 68.74% from its current price of $4.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $4.03.
Fair Value
-
According to the consensus of 3 analysts, Kodiak Sciences has 68.74% upside to fair value with a price target of $6.80 per share.
KOD vs. S&P 500
-
Over the past 5 trading days, Kodiak Sciences has overperformed the S&P 500 by 2.04% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kodiak Sciences does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kodiak Sciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Kodiak Sciences reported revenues of --.
Earnings Growth
-
Kodiak Sciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kodiak Sciences reported earnings per share of -$0.84.
Enterprise value:
44.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.38x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$341.4M | -$277.3M | -$186.8M | -$63.4M | -$46.2M | |
| EBITDA | -$322.8M | -$234.5M | -$149.5M | -$52.9M | -$37.4M | |
| Diluted EPS | -$6.39 | -$4.96 | -$3.36 | -$1.13 | -$0.84 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $972M | $734.8M | $486M | $289.3M | $171.9M | |
| Total Assets | $1.1B | $904.2M | $666.6M | $479.4M | $335.6M | |
| Current Liabilities | $31.4M | $64.7M | $52.5M | $41.7M | $25.6M | |
| Total Liabilities | $206.6M | $240.9M | $230.5M | $213.6M | $185.3M | |
| Total Equity | $860.8M | $663.3M | $436.2M | $265.8M | $150.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$206.5M | -$154.2M | -$117.3M | -$32.2M | -$30.1M | |
| Cash From Investing | -$336.5M | $249.2M | -$755K | -$27.8M | -$124K | |
| Cash From Financing | $1.9M | $31K | $501K | -$124K | $404K | |
| Free Cash Flow | -$253.8M | -$195.6M | -$117.7M | -$59.7M | -$30.2M | |
KOD
Sector
Market Cap
$212.6M
$34.7M
Price % of 52-Week High
34.74%
44.12%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.67%
1-Year Price Total Return
5.22%
-40.33%
Beta (5-Year)
2.425
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.17
200-day SMA
Sell
Level
$4.56
Bollinger Bands (100)
Sell
Level
2.89 - 7.71
Chaikin Money Flow
Buy
Level
7.2M
20-day SMA
Buy
Level
$3.86
Relative Strength Index (RSI14)
Buy
Level
54.34
ADX Line
Buy
Level
38.14
Williams %R
Neutral
Level
-75
50-day SMA
Buy
Level
$3.37
MACD (12, 26)
Buy
Level
0.23
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Sell
Level
-5.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Stock Forecast FAQ
In the current month, KOD has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The KOD average analyst price target in the past 3 months is $6.80.
-
Where Will Kodiak Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kodiak Sciences share price will rise to $6.80 per share over the next 12 months.
-
What Do Analysts Say About Kodiak Sciences?
Analysts are divided on their view about Kodiak Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kodiak Sciences is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Kodiak Sciences's Price Target?
The price target for Kodiak Sciences over the next 1-year time period is forecast to be $6.80 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is KOD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kodiak Sciences is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of KOD?
You can purchase shares of Kodiak Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kodiak Sciences shares.
-
What Is The Kodiak Sciences Share Price Today?
Kodiak Sciences was last trading at $4.07 per share. This represents the most recent stock quote for Kodiak Sciences. Yesterday, Kodiak Sciences closed at $4.03 per share.
-
How To Buy Kodiak Sciences Stock Online?
In order to purchase Kodiak Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Which Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Is Gartner a Safe Stock to Own?
Gartner (NYSE:IT) is among the world’s largest consulting, research and…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 44x
Alerts
Buy
57
RGC alert for May 14
Regencell Bioscience Holdings [RGC] is down 31.81% over the past day.
Buy
54
HALO alert for May 14
Halozyme Therapeutics [HALO] is down 24.57% over the past day.
Buy
91
COIN alert for May 14
Coinbase Global [COIN] is up 24.64% over the past day.
